Combination products

Combination treatment significantly increases chance of five-year Alzheimer’s survival, study results show

Experts said the large study had found "small but significant effects" of combination treatment with donepezil and memantine in Alzheimer's disease.…

Combination treatment before surgery improves melanoma survival rates, study results show

The 12-month event-free survival rate for patients with macroscopic stage III node-positive melanoma was 83.7% with the combination treatment, compared with 57.2% for adjuvant therapy alone.…

Power of one: what is holding polypills back?

Single pills with fixed-dose combinations of several medicines are not commonplace for the treatment of cardiovascular disease. As the first randomised controlled trial to show a polypill can cut the risk of heart attacks is published, we look at why, nearly two decades after it was first proposed, …

Combination treatment for hepatitis C approved by FDA

The US Food and Drug Administration (FDA) has approved the use of the combination treatment Vosevi (sofosbuvir, velpatasvir and voxilaprevir) for the treatment of adults with chronic hepatitis C virus (HCV) genotypes 1–6 without cirrhosis or with mild cirrhosis.…

Modelling approach could optimise drug combination choice

Researchers used polynomial modelling to simulate complex drug-dose effects and found that they could accurately predict the dose-effect function of drug combinations.…

COPD patients who use opioids at risk from respiratory complications

Older patients with chronic obstructive pulmonary disease who take opioids to relieve their symptoms increase their risk of dying from a respiratory-related complication compared with non-opioid users, according to new research.…

Combination immunotherapy for advanced melanoma gets early approval from NICE

The immunotherapy combination nivolumab/ipilimumab has been recommended for patients with advanced malignant melanoma, according to draft guidance from the National Institute for Health and Care Excellence (NICE).  The approval means that patients in England and Wales will be the first in…

High-risk women need more frequent doses of HIV drugs

Researchers say more frequent pre-exposure prophylaxis is required to protect women from HIV.…

Palbociclib drug combination slows advanced breast cancer

Combining the first-in-class targeted drug palbociclib with the hormone drug fulvestrant delays the progression of advanced breast cancer by an average of nine months — twice as long as when fulvestrant was given alone — a study shows.…

HIV resistance to tenofovir surprisingly common

International study finds high proportion of HIV patients were resistant to cART drug tenofovir.…